Compare Ares Capital Corporation (ARCC) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ares Capital Corporation vs Tenet Healthcare Corporation — how do they compare? Ares Capital Corporation trades at $18.77 (market cap $13.48B), while Tenet Healthcare Corporation trades at $204.25 (market cap $17.59B). The key difference: Tenet Healthcare Corporation is the larger of the two by market cap, and Ares Capital Corporation pays a 10.22% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| ARCC | THC | |
|---|---|---|
Market Cap | $13.48B | $17.59B |
Sector | Financials | Health |
52-Week High | $23.25 | $244.80 |
52-Week Low | $17.45 | $148.38 |
Dividend Yield | 10.22% | — |
Enterprise Value | — | $27.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ares Capital (ARCC) trades at $18.78, up 2.01% on the day, with a bearish technical signal but strong analyst support. The stock shows a P/E of 11.52 and P/B of 0.96, trading below the consensus price target of $20.58. Recent earnings have missed expectations, with Q2 2026 results pending, while revenue declined to $1.51B in 2025 from $1.7B in 2024. A dividend of $0.48 is scheduled for payment on June 30, 2026, supporting income appeal amid mixed sentiment.
ARCC presents a value opportunity with a high dividend yield and undervaluation relative to analyst targets, but faces headwinds from earnings misses and a bearish technical outlook. Risks include revenue volatility and competitive pressures in the BDC space, though institutional buy ratings suggest confidence in recovery potential. Investors should weigh income stability against growth challenges.
Tenet Healthcare (THC) trades at $204.25, down 1.22% amid broader market weakness. The stock maintains strong fundamentals with a P/E of 10.62 and robust profitability metrics including 37.87% ROE. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $4.82 surpassing the $4.17 estimate. Technical indicators show bullish momentum despite overbought RSI readings, with support at $204 and resistance at $209.
The outlook remains positive with 81% analyst buy ratings and a $233.63 consensus price target representing 14% upside. Key risks include healthcare regulatory pressures and execution challenges in outpatient expansion. Earnings growth from the Ambulatory Care segment and defensive positioning during geopolitical tensions provide catalysts for continued appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
